Durvalumab + Eribulin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-Negative Metastatic Breast Cancer
Conditions
HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
Trial Timeline
May 17, 2018 → Feb 10, 2020
NCT ID
NCT03430518About Durvalumab + Eribulin
Durvalumab + Eribulin is a phase 1 stage product being developed by Eisai for HER2-Negative Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03430518. Target conditions include HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03430518 | Phase 1 | Completed |
Competing Products
19 competing products in HER2-Negative Metastatic Breast Cancer